(Yicai Global) June 27 -- A joint venture between fast-growing Chinese drug developer Wuxi AppTec and US biopharma firm Juno Therapeutics has received approvals from China's regulators to proceed with a clinical trial of a new CAR-T cell immunotherapy.

China Food and Drug Administration gave the green-light to JW Therapeutics for the trial of the therapy, which is a new cure for tumors and especially effective against acute leukemia and Non-Hodgkin Lymphoma, 21st Century Business Herald reported today.

Chinese regulators have received clinical applications for dozens of CAR-T cell therapy products. There are 244 registered CAR-T projects in development worldwide, and China represents the largest market with 133 projects, ahead of 72 in the US.

Nanjing Legend Biotech, a subsidiary of GenScript Biotech became the first firm to obtain approvals for CAR-T clinical trials in late March.

Editor: William Clegg